The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Multicenter trial for assessing tolerability of combination therapy with cisplatin, irinotecan, and PSK in extensive-stage small-cell lung cancer: RNCLC-01 study.
Tatsuhiko Kashii
No relevant relationships to disclose
Toshiro Miwa
No relevant relationships to disclose
Shinya Kajiura
No relevant relationships to disclose
Ichiro Kinoshita
No relevant relationships to disclose
Satoshi Oizumi
No relevant relationships to disclose
Ken Nakagawa
No relevant relationships to disclose
Seisuke Nagase
No relevant relationships to disclose
Yusaku Akashi
No relevant relationships to disclose
Minoru Takada
No relevant relationships to disclose
Yasuo Iwamoto
No relevant relationships to disclose
Masahiro Tsuboi
No relevant relationships to disclose